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The adenomatous polyposis coli (APC) gene is a multi-
functional tumor suppressor mutated in over 80% of col-
orectal cancers (CRC). Mutations in APC are believed to
be one of the earliest events that contribute to CRC
initiation. APC has been implicated in the negative regu-
lation of the canonical Wnt signaling pathway, cell cycle
control, cell migration, differentiation, and apoptosis.
However, there remain many unanswered questions
about the precise roles of APC in CRC progression. For
example, over 90% of APC mutations result in truncated
proteins, among which termination mutations at codons
1309 and 1450 occur the most frequently. It is completely
unclear why the vast majority of human colon cancers
would retain truncated APC proteins unless there was
some survival/growth advantage to the emerging tumor.
We hypothesized that these truncated APC proteins may
actually play a dominant (gain of function) role in the
initiation and/or progression of CRC and have conducted
experiments to test this idea. Our rationale for these
experiments is there are no disease-specific targeted
treatments for CRC and therapeutic agents targeting
APC truncations could be beneficial.
We developed a unique series of telomerase (TERT)
and CDK4 immortalized human colonic epithelial cell
(HCEC) lines and experimentally made isogenic deriva-
tives by ectopic expression of the most commonly
observed APC truncations found in patients. In addition,
we made TERT and CDK4 expressing HCECs with TP53
and APC knockdowns as well as ectopic expression of
oncogenic KRASv12. We have completed a cell-based
high-throughput screen within UT Southwestern’s
200,000 compound library utilizing the most cancer pro-
gressed isogenic cell line and tested the initial hits against
the TERT immortalized normal diploid HCECs. A small
molecule lead compound, TASIN-1 (truncated APC
selective inhibitor), was identified from this screen that is
selectively toxic towards a panel of colon cancer cell lines
with APC truncations while sparing normal diploid
HCECs and cancer cells with wild type APC. TASIN-1
and its analogs (with IC50s from 0.01nM to 5µM) repre-
sent a novel strategy for the treatment of colon cancer. In
vitro and in vivo preclinical results will be presented.
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